Evolus, Inc. (EOLS): Price and Financial Metrics
Evolus, Inc. (EOLS)
Today's Latest Price: $13.97 USD
0.17 (-1.20%)
Updated Nov 21 6:55pm
Add EOLS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
EOLS Stock Summary
- Evolus Inc's stock had its IPO on February 8, 2018, making it an older stock than merely 3.7% of US equities in our set.
- EOLS's price/sales ratio is 27.23; that's higher than the P/S ratio of 96.06% of US stocks.
- Revenue growth over the past 12 months for Evolus Inc comes in at 569.75%, a number that bests 98.77% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Evolus Inc, a group of peers worth examining would be APHA, ADES, MNKD, QD, and BBU.
- Visit EOLS's SEC page to see the company's official filings. To visit the company's web site, go to www.evolus.com.
EOLS Daily Price Range
EOLS 52-Week Price Range
EOLS Stock Price Chart More Charts
EOLS Price/Volume Stats
| Current price | $13.97 |
| Prev. close | $14.14 |
| Day low | $13.75 |
| Day high | $14.05 |
| 50-day MA | $15.56 |
| 200-day MA | $18.75 |
| 52-week high | $30.25 |
| 52-week low | $10.22 |
| Volume | 424,400 |
| Avg. volume | 767,077 |
| Dividend yield | N/A |
| Market Cap | 466.95M |
Evolus, Inc. (EOLS) Company Bio
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Top Stories View All
Best & Worst Performing Stock Industries for November 21, 2019
Best & Worst Performing Small Cap Stocks for November 21, 2019
Best & Worst Performing Mid Cap Stocks for November 21, 2019
Best & Worst Performing Large Cap Stocks for November 21, 2019
Best & Worst Performing Mega Cap Stocks for November 21, 2019
View All Top Stories
Loading social stream, please wait...